HC Wainwright Raises Novavax (NASDAQ:NVAX) Price Target to $17.00

Novavax (NASDAQ:NVAX) had its price objective hoisted by HC Wainwright from $10.00 to $17.00 in a report issued on Wednesday morning, Briefing.com Automated Import reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on NVAX. ValuEngine raised shares of Novavax from a sell rating to a hold rating in a report on Thursday, August 1st. Oppenheimer boosted their price objective on shares of Novavax from $1.25 to $25.00 in a report on Monday, May 13th. Zacks Investment Research raised shares of Novavax from a hold rating to a buy rating and set a $8.00 price objective on the stock in a report on Thursday, May 16th. Chardan Capital reissued a neutral rating and set a $7.00 price objective on shares of Novavax in a report on Friday, May 10th. Finally, Cantor Fitzgerald reissued a hold rating on shares of Novavax in a report on Thursday, May 9th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $40.70.

Shares of NVAX opened at $7.84 on Wednesday. The firm has a market capitalization of $144.49 million, a PE ratio of -0.78 and a beta of 2.21. Novavax has a 1-year low of $4.01 and a 1-year high of $51.60. The company’s fifty day moving average price is $4.82 and its 200-day moving average price is $3.17.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.08). The firm had revenue of $3.36 million for the quarter, compared to analysts’ expectations of $3.53 million. During the same quarter in the previous year, the business earned ($2.40) earnings per share. On average, equities research analysts forecast that Novavax will post -5.81 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Oppenheimer & Co. Inc. purchased a new stake in Novavax in the first quarter valued at $40,000. Wedbush Securities Inc. boosted its holdings in Novavax by 102.1% in the first quarter. Wedbush Securities Inc. now owns 54,444 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 27,500 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Novavax by 21.8% in the first quarter. DekaBank Deutsche Girozentrale now owns 123,100 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 22,000 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Novavax by 3,799.2% in the first quarter. SG Americas Securities LLC now owns 435,107 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 423,948 shares during the last quarter. Finally, Creative Planning boosted its holdings in Novavax by 161.7% in the first quarter. Creative Planning now owns 513,324 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 317,204 shares during the last quarter.

About Novavax

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

See Also: Does a trade war provide a risk to the global economy?

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit